Shingles Vaccine and Alzheimer Prevention: What the UK Evidence Says in 2026

NHS Shingrix prevents shingles and post-herpetic neuralgia, and a growing 2024-2026 evidence base links it with a 17 to 33 percent lower dementia risk over 6 to 7 years. The UK Shingrix programme covers adults turning 65, the 70 to 79 catch-up cohort, and severely immunosuppressed adults aged 18 and over.

Picture the NHS letter on the kitchen table. You have just turned 65, or perhaps you are in your seventies, and the invitation is for the shingles vaccine, Shingrix. You might know someone who has had shingles, and you may well know someone living with dementia. Over the past two years, a series of remarkable studies from the UK and the United States have linked this very vaccine to a lower risk of developing Alzheimer disease and other dementias. As your GP practice, we want to walk you through this evidence calmly and honestly. We will cover what shingles is, the important Welsh natural experiment, the analyses of the newer Shingrix vaccine, why the adjuvant in the jab might matter, what the NHS actually says in 2026, and the practical question of whether you should have it. This is not about hype. It is about giving you the clear picture so you can make an informed choice.

Why shingles matters in the UK after 60

Shingles is caused by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. After you recover from chickenpox, usually in childhood, the virus lies dormant in your nerve roots. As we age, our cell-mediated immunity to the virus naturally declines. This allows the virus to reactivate, causing shingles. About one in four UK adults will experience shingles in their lifetime, and the risk rises steeply after the age of 60. The classic presentation is a tingling or burning patch of skin on one side of the body or face for a few days, followed by a band of painful, blistering rash. While the rash usually settles within two to four weeks, the most feared complication is post-herpetic neuralgia (PHN). This is persistent nerve pain that can last for months or even years after the rash has gone, and it affects up to one in five over-60s who get shingles. Other complications include shingles in or around the eye, which can threaten sight, Ramsay Hunt syndrome affecting the face and ear, and bacterial skin infections. UK studies from 2024 and 2025 have also highlighted a small but real increase in the risk of major cardiovascular events, such as a stroke or heart attack, in the months following a shingles episode. The NHS Shingrix vaccine is over 90 percent effective at preventing shingles and its complications, with protection lasting at least a decade. This is a powerful reason to accept the jab on its own merits.

The Welsh natural experiment that started the conversation

The most compelling evidence linking shingles vaccination to dementia risk comes from a natural experiment in Wales. In September 2013, Wales introduced the older live-attenuated shingles vaccine, Zostavax. Eligibility was determined by a strict date-of-birth cut-off. If you were born before 2 September 1933, you were permanently ineligible. If you were born on or after that date, you were eligible. This created two groups of people of very similar age, but only one could easily get the vaccine. Researchers, led by Dr Markus Eyting and Dr Pascal Geldsetzer, used anonymised Welsh NHS records to track new dementia diagnoses over seven years. The difference in vaccine uptake at the cut-off was dramatic, jumping from less than one percent among those just too old to nearly half of those just young enough. The results, published in the journal Nature in April 2025, showed that being eligible for the Zostavax vaccine was associated with a 20 percent lower probability of receiving a new dementia diagnosis over the following seven years. The effect was more pronounced in women than in men. Because the date-of-birth cut-off was effectively random, this study design controls for the ‘healthy-vaccinee bias’ better than any previous research. It does not prove the vaccine causes a reduction in dementia risk in the strictest sense, but it is the strongest causal evidence we have without a decades-long randomised trial.

Shingrix replaced Zostavax, and the dementia signal got stronger

The NHS replaced the live Zostavax vaccine with Shingrix in September 2023. Shingrix is a recombinant vaccine, meaning it uses only a part of the virus, and it contains a powerful adjuvant called AS01 to boost the immune response. It is more effective and provides longer-lasting protection against shingles than Zostavax did. The natural question was whether this newer, stronger vaccine would show a similar or even greater effect on dementia. A 2024 study published in Nature Medicine, led by researchers from Oxford and using US electronic health records, looked at over 200,000 adults who were switched from Zostavax to Shingrix during the US rollout. It found that Shingrix recipients had a 17 percent longer dementia-free period over six years, equating to about 164 additional days lived without a dementia diagnosis. Then, in early 2026, a study in Nature Communications analysed data from 1.5 million US Medicare beneficiaries. It reported that receiving the full two-dose course of Shingrix was associated with a 33 percent lower risk of dementia overall, a 28 percent lower risk of Alzheimer disease, and a 33 percent lower risk of vascular dementia during the follow-up period. As with the Welsh data, the effects were larger in women. It is important to remember these are observational studies, but they examine the vaccine the NHS now uses. The consistency of the findings across different populations and methods makes random chance an unlikely explanation. The signal is real and solid, even if the precise cause is still being debated.

Mechanism debate: anti-virus or AS01 adjuvant

Scientists are exploring two main theories to explain how the shingles vaccine might reduce dementia risk. The first is the direct antiviral effect. The varicella-zoster virus can reactivate at a low level without causing a full shingles rash. This subclinical reactivation can drive inflammation in the brain and blood vessels, potentially triggering or accelerating the amyloid and tau pathology seen in Alzheimer disease. This ‘herpes virus theory’ of Alzheimer disease has been gaining support for years. By preventing reactivation, the vaccine could stop this recurring neurological insult. The second theory focuses on the AS01 adjuvant, the ingredient in Shingrix that makes the immune response so strong. A 2025 study in npj Vaccines compared Shingrix with the AS01-adjuvanted RSV vaccine, Arexvy, in over 400,000 older adults. It found both vaccines were associated with a similar reduction in dementia risk over 18 months. This suggests the benefit may come from the adjuvant itself ‘training’ the ageing immune system to behave more youthfully, a concept called trained immunity, which could reduce harmful brain inflammation. The most likely answer is that both mechanisms play a role. For you as a patient, the precise reason is academic in 2026. You are receiving Shingrix on the NHS, and it appears to reduce dementia risk regardless of how it works.

What does the NHS actually say in 2026

As of 2026, NHS England and the Joint Committee on Vaccination and Immunisation (JCVI) have not changed their advice on the shingles vaccine because of the dementia data. The official position remains that Shingrix is offered for its licensed indication: the prevention of shingles and post-herpetic neuralgia. The view is that the dementia evidence is promising and intriguing, but it is largely observational. No large-scale randomised controlled trials specifically designed to measure dementia outcomes have been conducted, and such trials would take decades. Therefore, any potential benefit against dementia is considered a possible bonus, not a reason in itself to recommend the vaccine. NICE has not endorsed Shingrix for dementia prevention. Organisations like Alzheimer’s Research UK have described the data as promising and encouraging, supporting the current recommendation to accept the vaccine for its primary purpose. The practical NHS details for 2026 are clear. If you are turning 65, you are eligible for two free doses of Shingrix. There is also a catch-up programme for adults aged 70 to 79. Severely immunosuppressed adults aged 18 and over are also eligible. Your eligibility runs until your 80th birthday, with the second dose given by your 81st. Your local NHS immunisation team or GP surgery will send you an invitation. If you are in the eligible age range and have not heard anything, it is worth contacting your GP receptionist to check.

Should you have the jab if you are eligible

For UK adults in the eligible groups, the answer is straightforward: yes, you should accept the vaccine. The benefit for preventing shingles and its painful complication, post-herpetic neuralgia, is excellent, with over 90 percent efficacy that lasts for many years. The associated risks of sight problems and cardiovascular events after a shingles episode make this indication alone very compelling for people over 60. When you add the developing evidence for a reduction in dementia risk, the case for vaccination becomes even stronger. The side effects are usually mild and short-lived, most commonly a sore arm, fatigue, muscle aches, and a mild fever for one to three days. These are signs of a strong immune response. Serious reactions are rare. The vaccine is given as two injections into the deltoid muscle of the upper arm, spaced six to twelve months apart. If you are not in the eligible group, the situation is different. The dementia evidence, while exciting, does not currently justify seeking private vaccination purely for dementia prevention outside of NHS advice. The full private course costs around 400 to 460 pounds at UK pharmacies in 2026. If you are considering this for shingles prevention itself and are willing to pay, that is a personal choice, but we would advise discussing it with your GP first.

What this evidence does NOT mean

It is important to be clear about what these studies do not show. They do not show that the Shingrix vaccine cures Alzheimer disease. They do not mean that if you have the vaccine you are immune to dementia. What they show is a relative reduction in the risk of receiving a new dementia diagnosis over a six to seven-year follow-up period. In absolute terms, the gain for an individual is modest, though it is meaningful for public health across the population. For example, if out of 100 unvaccinated adults followed for seven years, ten develop dementia, the evidence suggests that in a similar vaccinated group, about eight might develop dementia. That is two cases potentially avoided per hundred people. There are three key caveats. First, healthy-vaccinee bias is a real concern in observational studies; people who choose to be vaccinated often have healthier habits in general. The Welsh natural experiment design minimises this concern better than other studies. Second, the follow-up period is still relatively short. Dementia develops over decades, and we do not yet know if the seven-year signal translates into a reduced lifetime risk. Third, the effect may be linked to the AS01 adjuvant rather than the shingles virus itself. The evidence supports accepting the vaccine when offered and viewing any dementia benefit as a likely positive side effect. It does not support seeking out the vaccine privately in the hope of reversing existing memory problems.

Other things you can do for dementia risk in UK 2026

The shingles vaccine is one potential piece of a larger puzzle. The 2024 update of the Lancet Commission on dementia prevention identified 14 modifiable risk factors that together account for about 45 percent of dementia cases worldwide. For UK adults in their 60s and 70s, the highest-yield actions remain: keeping blood pressure well controlled, treating hearing loss with NHS-supplied hearing aids, taking 150 minutes of varied exercise each week, following a Mediterranean-style diet, keeping alcohol within the UK Chief Medical Officers’ limit of 14 units per week, not smoking, staying socially connected, and engaging in mentally stimulating activities. Good sleep hygiene is also important. In the UK in 2026, the free NHS Health Check for those aged 40 to 74 is a good opportunity to discuss brain health. While new anti-amyloid drugs like lecanemab have been approved by NICE for early Alzheimer disease under strict criteria, access is through specialist memory clinics and is not relevant to prevention for most people. Look after your heart, your hearing, and your body, and consider the shingles vaccine as another positive step you can take.

Frequently Asked Questions

Does the NHS recommend Shingrix specifically to prevent dementia?

No. In 2026, the NHS and JCVI advise Shingrix only for the prevention of shingles and post-herpetic neuralgia. Any potential benefit against dementia is considered a possible bonus, not the reason for vaccination. The official UK position is that more data, ideally from randomised trials, is needed before changing the programme’s guidance. Eligible adults should accept the jab for its proven shingles benefit.

How big is the effect on dementia risk?

The studies suggest about a 17 to 33 percent lower risk of a new dementia diagnosis over six to seven years of follow-up. The Welsh study showed 20 percent, the Oxford US study 17 percent, and the large US Medicare study 33 percent. The effects were consistently larger in women. The absolute risk reduction for an individual is small but meaningful at a population level. Long-term effects over a lifetime are not yet known.

Is it the vaccine or the AS01 adjuvant?

We do not know for certain yet. A 2025 study found that an RSV vaccine containing the same AS01 adjuvant was associated with a similar reduction in dementia risk as Shingrix. This points strongly to the adjuvant playing a key role. The alternative theory is that preventing shingles virus reactivation reduces brain inflammation. Both are plausible and may work together. For patients, the distinction is academic as you receive Shingrix on the NHS.

I had Zostavax years ago, should I have Shingrix now?

Yes, if you are now in the eligible age group. UK guidance is to offer Shingrix to all eligible adults, even if they previously received the older Zostavax vaccine. Shingrix is more effective and longer-lasting. There is no strict minimum gap required, but many GPs suggest waiting at least eight weeks after a Zostavax dose. If you had Zostavax recently, discuss the timing with your GP.

I am under 65 and have a strong family history of Alzheimer, can I have Shingrix privately?

You can pay for it privately at major UK pharmacies if you are over 50, at a cost of around 400 to 460 pounds for the two-dose course. The honest medical view is that the dementia evidence does not yet justify private vaccination on family-history grounds alone. If you want it for shingles prevention and have considered the cost, that is your choice. We recommend discussing it with your GP first.

Will the vaccine help if I already have mild cognitive impairment or early dementia?

A 2025 study suggested vaccination was associated with a slower progression from mild cognitive impairment to dementia and fewer dementia-related deaths in those already affected. The NHS does not currently vaccinate for this specific reason. If you are eligible for Shingrix anyway, this is another reason to accept the jab. Discuss it with the specialist managing your cognitive health.

Are there any UK trials I can join?

As of May 2026, there is no large randomised UK trial specifically testing Shingrix for dementia prevention. Several long-term observational studies are ongoing using data from UK Biobank and the Welsh SAIL databank. To express interest in future studies, you can ask your GP about signing up for the Join Dementia Research register.

I have just had Shingrix and feel rotten, is this normal?

Yes, it is quite common. Shingrix is known to be reactogenic. About one in six people feel unwell enough to need a quiet day. Sore arm, fatigue, muscle aches, and a mild fever for 24 to 72 hours are normal. Taking paracetamol or ibuprofen can help. If symptoms last longer than four days, are severe, or you develop a new rash, contact NHS 111 or your GP practice for advice.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.